Optimal care for familial hypercholesterolaemia (FH) requires patient-centred management,
multidisciplinary teamwork, involvement of primary care practitioners, patient networks …

The high occurrence of atherosclerotic cardiovascular disease (ASCVD) events is still a
major public health issue. Although a major determinant of ASCVD event reduction is the …

BACKGROUND Diagnostic tools for familial hypercholesterolemia (FH) rely on estimation of
LDL cholesterol concentration. However, routine measurement or calculation of LDL …

Recent studies have demonstrated that commercially available lipid‐lowering drugs cause
various side effects; therefore, searching for anti‐hyperlipidaemic compounds with lower …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a plasma protein that controls
cholesterol homeostasis. Here, we design a human PCSK9 mimic, named HIT01, with no …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a crucial role in the modulation
of lipid metabolism as a critical negative regulator of hepatic low-density lipoprotein receptor …

Familial hypercholesterolaemia (FH) is caused by pathogenic variants in LDLR, APOB or
PCSK9. Impaired low‐density lipoprotein (LDL) receptor function leads to decreased LDL …

Dyslipidemia is a major risk factor for cardiovascular disease, and its impact may be
exacerbated when accompanied by metabolic dysfunction-associated steatotic liver disease …

Introduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that
binds and promotes the lysosomal degradation of the low-density lipoprotein receptors …

While modern drug therapy has improved survival of patients with immune deficiency virus
(HIV) infection, the rate of myocardial infarction among affected individuals has increased by …